EGFR and non-small cell lung carcinoma: This innovative approach combines recombinase polymerase amplification technology with the collateral single-stranded DNase activity of Cas13, enabling highly sensitive and specific detection of cancer-associated mutations in cell-free DNA, such as the EGFR-T790M and EGFR-L858R mutations observed in patients with non-small-cell lung carcinoma (NSCLC) [163].